Reportedly, Amgen (AMGN) announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member of the Board’s Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee. Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent.
From 2014 to 2020, Dr. Drake served as president of The Ohio State University (OSU). He completed his undergraduate degree from Stanford University and is a medical doctorate from the University of California, San Francisco.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces that Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle Guse, GC & CFO will present at Tribe Public’s Webinar Presentation and Q&A Event that is scheduled to begin at 8am pacific/11am eastern on Thursday, August 25th. During this complimentary event, Atossa management will speak new opportunities for its inhalation therapy, AT-H201, to potentially treat lung injury caused by cancer treatment and will be available for a Q&A session focused on Atossa’s research programs and future development. To join the complimentary event, please register at ATOSAUG25.TribePublic.com. Once registered, Tribe members may then send their questions for Atossa’s management to email@example.com. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.
About Tribe Public LLC
Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe’s events focus on issues that the Tribe’s members care about with an emphasis on hosting management teams and experts from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress, and plans. Tribe members primarily include Institutions, Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers at the Tribe Public website via the Tribe’s FREE “Wish List” process. Visit Tribe Public’s Website http://www.tribepublic.com/ to join the Tribe and express your interests today.